Enjaymo™(sutimlimab-jome) – New orphan drug approval
February 4, 2022 - The FDA announced the approval of Sanofi’s Enjaymo (sutimlimab-jome), to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD).
Download PDF
